Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Hims & Hers Health, Inc. (HIMS) vs Dr. Reddy's Laboratories Ltd (RDY)

Hims & Hers Health, Inc. and Dr. Reddy's Laboratories Ltd are both Drug Manufacturers Specialty & Generic companies. Dr. Reddy's Laboratories Ltd is the larger, with a market value of $10.0B against $6.9B — 1.5× the size. Hims & Hers Health, Inc. has negative trailing earnings, so its P/E is not meaningful; Dr. Reddy's Laboratories Ltd trades at 30.8×. Hims & Hers Health, Inc. grew revenue faster over the last twelve months: 28.0% against −11.6%. Dr. Reddy's Laboratories Ltd has the higher net margin (9.81% vs −5.51%) and the higher return on invested capital (5.89% vs −11.4%). Across the 20 metrics below, Dr. Reddy's Laboratories Ltd leads on 15 and Hims & Hers Health, Inc. on 5.

Valuation

Metric HIMS RDY Drug Manufacturers Specialty & Generic median
P/E n/m 30.85 20.14
P/S 2.65 2.79 2.25
P/B 21.07 2.35 1.90
Price to free cash flow 82.23 69.03 16.54
EV/EBITDA n/m 15.92 12.29
EV/Sales 2.85 2.76 2.56
Earnings yield (2.07%) 3.24% (2.99%)
Free cash flow yield 1.22% 1.45% 0.00%

Profitability

Metric HIMS RDY Drug Manufacturers Specialty & Generic median
Gross margin 68.43% 50.00% 53.94%
Operating margin (5.99%) 10.91% 0.00%
Net margin (5.51%) 9.81% 0.00%
Free cash flow margin 3.22% 4.05% 0.00%
Return on equity (32.03%) 8.21% (0.40%)
Return on assets (5.16%) 5.55% (3.32%)
Return on invested capital (11.38%) 5.89% 0.00%

Growth

Metric HIMS RDY Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 28.04% (11.60%) 10.01%
EPS growth (last fiscal year) (3.77%) (30.38%) —
Revenue growth, 5-year CAGR 53.90% 6.66% 6.74%
Net income growth, 5-year CAGR 0.00% 14.08% 0.00%

Health

Metric HIMS RDY Drug Manufacturers Specialty & Generic median
Debt to equity 4.21 0.19 0.05
Current ratio 0.93 1.90 2.31
Net debt to EBITDA 2.43 (0.15) 0.85

Dividend

Metric HIMS RDY Drug Manufacturers Specialty & Generic median
Dividend yield — 0.66% 1.70%
Payout ratio 0.00 0.14 0.00

Size

Metric HIMS RDY Drug Manufacturers Specialty & Generic median
Market cap 6.87b 10.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack